Niaprazine
CAS: 27367-90-4
Ref. 3D-FN104313
10mg | 144.00 € | ||
25mg | 271.00 € | ||
50mg | 406.00 € | ||
100mg | 543.00 € | ||
250mg | 863.00 € |
Product Information
- 1709 Cerm
- 1709Cerm
- 3-Pyridinecarboxamide, N-(3-(4-(4-fluorophenyl)-1-piperazinyl)-1-methylpropyl)- (9CI)
- 3-Pyridinecarboxamide, N-[3-[4-(4-fluorophenyl)-1-piperazinyl]-1-methylpropyl]-
- Brn 0844157
- N-(3-(4-(4-Fluorophenyl)-1-piperazinyl)-1-methylpropyl)-3-pyridinecarboxamide
- N-(3-(4-(p-Fluorophenyl)-1-piperazinyl)-1-methylpropyl)nicotinamide
- N-{4-[4-(4-fluorophenyl)piperazin-1-yl]butan-2-yl}pyridine-3-carboxamide
- Niaprazina
- Niaprazina [INN-Spanish]
- See more synonyms
- Niaprazine [INN:DCF]
- Niaprazinum
- Niaprazinum [INN-Latin]
- Nicotinamide, N-(3-(4-(p-fluorophenyl)-1-piperazinyl)-1-methylpropyl)-
- Nopron
- Unii-R2H3Yn6E3L
Niaprazine is a 5-HT2 receptor antagonist that has been used for the treatment of inflammatory bowel disease. It is available as an ester hydrochloride salt, which can be administered orally or parenterally. The drug may be used in conjunction with other drugs to treat symptoms of bowel disease such as abdominal pain, diarrhea, and constipation. Niaprazine has also been shown to have anti-inflammatory effects. It binds to 5-HT2 receptors and inhibits the release of proinflammatory mediators such as prostaglandins and leukotrienes that are involved in the pathogenesis of inflammatory bowel diseases. This mechanism is not well understood but may be due to its ability to inhibit phospholipase A2 enzyme activity or its inhibition of sodium citrate transport across the cell membrane. Niaprazine has also been shown to have some effect on preventing autoimmune diseases in animal models.
Chemical properties
Technical inquiry about: 3D-FN104313 Niaprazine
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.